Fei Ke

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 529 citations

Medicine, Oncology, Pharmacology +10

Neutrophil extracellular traps promote macrophage pyroptosis in sepsis

Linsong Chen, Yanfeng Zhao, Dengming Lai et al. · Cell Death and Disease · 2018 · 203 citations · Full text

Life Sciences, Cell Biology, Immunology +17

How Far Away Are Lithium-Sulfur Batteries From Commercialization?

Kunlei Zhu, Chao Wang, Zi‐Xiang Chi et al. · Frontiers in Energy Research · 2019 · 182 citations · Full text

Natural Sciences, Chemical Engineering, Materials Science +17

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

Bing Li, Shengxiang Ren, Xuefei Li et al. · Lung Cancer · 2013 · 178 citations

Medicine, Molecular Biology, Oncology +14

Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i>-mutant non-small cell lung cancer

Ningning Cheng, Weijing Cai, Shengxiang Ren et al. · Oncotarget · 2015 · 149 citations · Full text

Medicine, Molecular Biology, Oncology +17